Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi; Bertram Wiedenmann

doi:10.1038/s41571-018-0118-8

Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi, Bertram Wiedenmann

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article

Abstract

In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

Original language	English
Journal	Nature Reviews Clinical Oncology
DOIs	https://doi.org/10.1038/s41571-018-0118-8
Publication status	Accepted/In press - Jan 1 2018

Fingerprint

ASJC Scopus subject areas

Oncology

Cite this

Rindi, G., & Wiedenmann, B. (Accepted/In press). Neuroendocrine neoplasia goes molecular — time for a change. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-018-0118-8

@article{0e08a528f16f48a2a5c834fe2478efd5,

title = "Neuroendocrine neoplasia goes molecular — time for a change",

abstract = "In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.",

author = "Guido Rindi and Bertram Wiedenmann",

year = "2018",

month = jan

day = "1",

doi = "10.1038/s41571-018-0118-8",

language = "English",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neuroendocrine neoplasia goes molecular — time for a change

AU - Rindi, Guido

AU - Wiedenmann, Bertram

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

AB - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=85056124055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056124055&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0118-8

DO - 10.1038/s41571-018-0118-8

M3 - Article

AN - SCOPUS:85056124055

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -

Access to Document

10.1038/s41571-018-0118-8